• 1.貴陽市第一人民醫(yī)院普外科(貴陽550002);;
  • 2.大連大學(xué)附屬中山醫(yī)院普外科(大連116001);

目的 　探討c-met mRNA在乳腺癌患者術(shù)后腋窩引流液中表達(dá)的意義。
方法 　用RT-PCR法檢測(cè)乳腺癌患者術(shù)后腋窩引流液中c-met mRNA的表達(dá)，分析其表達(dá)與腫瘤大小、腋窩淋巴結(jié)轉(zhuǎn)移、雌激素受體（estrogen receptor,ER）、孕激素受體（progesterone receptor,PR）及生長(zhǎng)因子受體2（c-erbB-2）的關(guān)系，以及5-FU加蒸餾水沖洗手術(shù)野對(duì)c-met mRNA表達(dá)的影響。
結(jié)果 ?、賑-met mRNA能在乳腺癌術(shù)后腋窩引流液中表達(dá)，其陽性率高于病理檢查腋窩淋巴結(jié)轉(zhuǎn)移的陽性率(P＜0.05)。②腋窩淋巴結(jié)轉(zhuǎn)移、腫瘤大小與c-met mRNA的表達(dá)有關(guān)。③腫瘤ER、PR 及c-erbB-2的表達(dá)與c-met mRNA的表達(dá)無關(guān)。④5-FU加蒸餾水沖洗手術(shù)創(chuàng)面能明顯降低c-met mRNA的表達(dá)。
結(jié)論 　c-met mRNA是乳腺癌微轉(zhuǎn)移研究的理想特異性標(biāo)志物，與常規(guī)病理檢查腋窩淋巴結(jié)相比，RT-PCR檢測(cè)腋窩引流液中c-met mRNA的表達(dá)能更早檢測(cè)出腫瘤細(xì)胞在胸壁淋巴管中的轉(zhuǎn)移，并具有更高的準(zhǔn)確性。

引用本文： 楊衛(wèi)軍,黃志剛,李春來,吳正陽,尹家俊. c-met mRNA在乳腺癌術(shù)后腋窩引流液中表達(dá)的意義. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(3): 259-262. doi: 復(fù)制

1. 傅西林， 張立華， 張國珩. 常規(guī)檢查淋巴結(jié)轉(zhuǎn)移陰性之乳腺癌腋窩組織再連續(xù)切片檢查的研究 [J]. 中國腫瘤臨床， 1985； 12（1）∶20.
2. 陳朝倫， 盧曉梅， 黃絨， 等. Ⅰ期癌癥患者切除淋巴結(jié)內(nèi)隱匿性微小轉(zhuǎn)移癌灶的檢查及其臨床病理意義 [J]. 中華腫瘤雜志， 1997； 19(1)∶69.
3. Gardner B, Feldman J. Are positive axillary nodes in breast ca-ncer markers for incurable disease? [J]. Ann Surg， 1993; 218(3)∶270.
4. Noguchi M. Sentinel lymph node biopsy and breast cancer [J]. Br J Surg， 2002; 89(1)∶21.
5. 張維銘. 現(xiàn)代分子生物學(xué)實(shí)驗(yàn)手冊(cè) [M]. 北京： 科學(xué)出版社， 2003∶103~106.
6. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model [J]. Cancer Res， 2001; 61(20)∶7518.
7. Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte gr-owth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis， 2001; 22(7)∶1035.
8. Wang Y, Selden AC, Morgan N, et al. Hepatocyte growth factor/scatter factor expression in human mammary epithelium [J]. Am J Pathol， 1994; 144(4)∶675.
9. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [J]. Cancer Res， 1994; 54(7)∶1630.
10. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues [J]. Oncogene， 1991; 6(11)∶1997.
11. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer [J]. Biochem Biophys Res Commun， 1992; 189(1)∶227.
12. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas [J]. Oncogene， 1992; 7(12)∶2549.
13. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene， 1992; 7(1)∶181.
14. 陳顯玉， 喻梅英， 楊竹林, 等. 乳腺良惡性病變組織c-met蛋白和轉(zhuǎn)化生長(zhǎng)因子α的表達(dá)及意義 [J]. 中國普外基礎(chǔ)與臨床雜志, 1999; 6(2)∶81.
15. 尹家俊， 宋燕. 肝細(xì)胞生長(zhǎng)因子及受體c-met在乳腺癌中的研究進(jìn)展 [J]. 中國普外基礎(chǔ)與臨床雜志, 2000; 7(5)∶347.
16. Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors [J]. Cancer， 2003; 97(8)∶1841.
17. Tsarfaty I, Alvord WG, Resau JH, et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas [J]. Anal Quant Cytol Histol， 1999; 21(5)∶397.
18. Ghoussoub RA, Dillon DA, D’Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma [J]. Cancer， 1998; 82(8)∶1513.
19. 徐叔云主編. 中華臨床藥物學(xué) [M]. 北京： 人民衛(wèi)生出版社， 2003∶1429.
20. Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients [J]. Anticancer Res， 1995; 15(4)∶1543.
  1. 1. 傅西林， 張立華， 張國珩. 常規(guī)檢查淋巴結(jié)轉(zhuǎn)移陰性之乳腺癌腋窩組織再連續(xù)切片檢查的研究 [J]. 中國腫瘤臨床， 1985； 12（1）∶20.
  2. 2. 陳朝倫， 盧曉梅， 黃絨， 等. Ⅰ期癌癥患者切除淋巴結(jié)內(nèi)隱匿性微小轉(zhuǎn)移癌灶的檢查及其臨床病理意義 [J]. 中華腫瘤雜志， 1997； 19(1)∶69.
  3. 3. Gardner B, Feldman J. Are positive axillary nodes in breast ca-ncer markers for incurable disease? [J]. Ann Surg， 1993; 218(3)∶270.
  4. 4. Noguchi M. Sentinel lymph node biopsy and breast cancer [J]. Br J Surg， 2002; 89(1)∶21.
  5. 5. 張維銘. 現(xiàn)代分子生物學(xué)實(shí)驗(yàn)手冊(cè) [M]. 北京： 科學(xué)出版社， 2003∶103~106.
  6. 6. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model [J]. Cancer Res， 2001; 61(20)∶7518.
  7. 7. Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte gr-owth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis， 2001; 22(7)∶1035.
  8. 8. Wang Y, Selden AC, Morgan N, et al. Hepatocyte growth factor/scatter factor expression in human mammary epithelium [J]. Am J Pathol， 1994; 144(4)∶675.
  9. 9. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [J]. Cancer Res， 1994; 54(7)∶1630.
  10. 10. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues [J]. Oncogene， 1991; 6(11)∶1997.
  11. 11. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer [J]. Biochem Biophys Res Commun， 1992; 189(1)∶227.
  12. 12. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas [J]. Oncogene， 1992; 7(12)∶2549.
  13. 13. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene， 1992; 7(1)∶181.
  14. 14. 陳顯玉， 喻梅英， 楊竹林, 等. 乳腺良惡性病變組織c-met蛋白和轉(zhuǎn)化生長(zhǎng)因子α的表達(dá)及意義 [J]. 中國普外基礎(chǔ)與臨床雜志, 1999; 6(2)∶81.
  15. 15. 尹家俊， 宋燕. 肝細(xì)胞生長(zhǎng)因子及受體c-met在乳腺癌中的研究進(jìn)展 [J]. 中國普外基礎(chǔ)與臨床雜志, 2000; 7(5)∶347.
  16. 16. Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors [J]. Cancer， 2003; 97(8)∶1841.
  17. 17. Tsarfaty I, Alvord WG, Resau JH, et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas [J]. Anal Quant Cytol Histol， 1999; 21(5)∶397.
  18. 18. Ghoussoub RA, Dillon DA, D’Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma [J]. Cancer， 1998; 82(8)∶1513.
  19. 19. 徐叔云主編. 中華臨床藥物學(xué) [M]. 北京： 人民衛(wèi)生出版社， 2003∶1429.
  20. 20. Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients [J]. Anticancer Res， 1995; 15(4)∶1543.